Staidson Biopharmaceuticals Hits Day Low of CNY 21.96 Amid Price Pressure

Staidson (Beijing) Biopharmaceuticals Co., Ltd. experienced a significant decline today, with the stock dropping by 5.73% and reaching an intraday low of CNY 21.96. This performance contrasts sharply with the China Shanghai Composite, which saw a modest gain of 1.28% on the same day. Over the past week, Staidson's stock has decreased by 7.15%, and its monthly performance reflects a more substantial decline of 20.42%. Year-to-date, the stock has lost 18.67%, while its one-year performance shows a notable drop of 36.41%. In contrast, the China Shanghai Composite has gained 17.95% over the past year. The company's financial metrics indicate challenges, including a negative net worth and a low return on capital employed (ROCE) of 0%. Staidson has reported losses for six consecutive quarters, with net sales declining at an annual rate of 15.81%. The stock's performance has been particularly concerning, as it has underperformed the market significantly, generating negative returns while the broader market has seen positive growth.